"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

AI-driven MRI solution, icobrain aria receives US FDA clearance for safer Alzheimer’s treatment: Boston Saturday, November 16, 2024, 16:00 Hrs [IST] icometrix, a g ...

A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

Doctors are most concerned about the new US Health Secretary's unwarranted criticisms of vaccine safety - here his other ...

For Biogen, an expensive gamble has paid off, as even with accelerated approval the company stands to make billions of dollars from aducanumab, given it estimates there are around 1.5 million ...

HMTM previously failed a phase 3 trial reported in 2016, and it remains to be seen whether the FDA will ... its approval of Biogen/Eisai's pathfinder amyloid drug Aduhelm (aducanumab) on mixed ...

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...

The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with relapsed/refractory acute leukemia and a lysine methyltransferase 2A gene ( ...

The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...